FDA out­lines prod­uct de­vel­op­ment process to com­bat Wuhan coro­n­avirus

The FDA on Mon­day is­sued a state­ment ex­plain­ing how the agency can fa­cil­i­tate the de­vel­op­ment of in­ves­ti­ga­tion­al prod­ucts to di­ag­nose, treat and pre­vent emerg­ing pub­lic health threats such as the nov­el coro­n­avirus (2019-nCoV) that emerged in Wuhan, Chi­na in De­cem­ber.

“We are ac­tive­ly lever­ag­ing the vast breadth of the FDA’s ex­per­tise and have be­gun em­ploy­ing the full range of our pub­lic health au­thor­i­ties to fa­cil­i­tate the de­vel­op­ment and avail­abil­i­ty of in­ves­ti­ga­tion­al med­ical prod­ucts to ad­dress this ur­gent pub­lic health sit­u­a­tion,” said FDA Com­mis­sion­er Stephen Hahn.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.